Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver.
A female neonate with diffuse hemangiomatosis and hepatic hemangiomas had cardiac insufficiency develop and had failure to thrive. Her disease was unresponsive to prednisone. She received two courses of cyclophosphamide 10 days apart and a final course 2.5 weeks later. Twelve days after the second course of cyclophosphamide, her liver was significantly smaller. She is now 6-years-old, well-developed, and has no signs of hepatomegaly, malnourishment, or heart failure. Cyclophosphamide appears to be a safe, effective, and rapid treatment of life-threatening hemangiomas of infancy.
Hurvitz
S A
SA
Division of Pediatric Hematology-Oncology, Ahmanson Pediatrics Center, Los Angeles, California, USA.
Hurvitz
C H
CH
Sloninsky
L
L
Sanford
M C
MC
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005183:Failure to Thrive / Q000209:etiology; D005260:Female; D006333:Heart Failure / Q000209:etiology; D006391:Hemangioma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide